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Abstract
Background Oral mucositis is a common complication in
pediatric cancer patients, affecting up to 80% of children.
Due to neutropenia and disruption of the mucosal barrier,
chemotherapy-induced oral mucositis is often complicated
by super-infections.
Case report A 16-years old male with stage 3 Burkitt’s
lymphoma developed chemotherapy induced oral mucositis
grade 3 (according to WHO scale). Ulcers were quickly
growing (reaching a maximum diameter of 3 cm) and
became greyish in colour, resulting in dysphagia and pain.
A swab of the lesions was taken and microbiological tests
were performed. The sample grew for Raoultella planti-
cola, an encapsulated Gram-negative bacterium whose full
pathogenic potential still needs to be defined. Treatment:
The patient received antibiotic combination therapy with
Amikacin and Ceftazidime for 8 days. Complete healing of
the lesions and resolution of the symptoms were reached
and he completed his antineoplastic therapy without further
complications. Follow-up: Twelve months after the infec-
tion, he is alive and well, with no oral complaints.
Conclusion This is the first report of a Raoultella planti-
cola infection in a patient with chemotherapy induced oral
mucositis. This type of infection must be added to the list
of organisms to be considered when caring for these
patients.
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Background
While early diagnosis and advances in cancer therapy for
children continue to improve survival rates, oral compli-
cations remain a significant cause of morbidity and
potential mortality. Oral mucositis (OM) is a common
complication in cancer patients receiving chemotherapy
with an incidence in the paediatric cancer population of
50–80% (Bardellini et al. 2013). OM initially presents as
erythema of the oral mucosa, which then often progresses
to erosion and ulceration; it can be very painful and it can
significantly affect nutritional intake, mouth care, and
overall quality of life, not to forget lengthening of hospital
stay and associated costs. In patients receiving
chemotherapy for solid tumours or lymphoma, the rate of
infection during cycles with mucositis is more than twice
that during cycles without mucositis and directly propor-
tional to the severity of mucositis (Elting et al. 2003).
Infection-related deaths are also more common during
cycles with both oral and gastro-intestinal mucositis. In
addition, the average duration of hospitalisation is signifi-
cantly longer during chemotherapy cycles with mucositis.
A reduction in the next dose of chemotherapy is twice as
common after cycles with mucositis than after cycles
without mucositis (Elting et al. 2003). Thus, mucositis and
related infections may lead to dose-limiting toxicity of
chemotherapy with fatal effects on patient survival.
Raoultella planticola (RP)—formerly known as Kleb-
siella planticola—is a Gram-negative, non-motile,
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facultative aerobic and lactose fermenting bacillus that is
primarily considered an environmental bacteria, belonging
to the Enterobacteriaceae family (Freney et al. 1984).
Raoultella planticola is mostly an aquatic, botanical and
soil organism and, usually, it is not considered a cause of
invasive infections in humans. Raoultella species produce
histidine decarboxylase and have been implicated in
scombroid (histamine) fish poisoning (Lam and Salit
2014). Long considered almost harmless to humans, this
environmental organism only recently has been reported as
the cause of several infections. The first case-report
appeared in 1984; however the pathogen responsible for
the infection was thought to be a Klebsiella species (Freney
et al. 1984). Only in 2001 was this pathogen reclassified as
belonging to a new different genus (Drancourt et al. 2001).
Several studies report that 9–18% of humans are colonised
by this bacterium (Freney et al. 1984; Podschun et al. 1998;
Westbrook et al. 2000). It has to be noted that RP shares
strong similarities with K. pneumoniae, in terms of
pathogenicity, virulence and drug-resistance mechanisms
(Murray et al. 2007). Raoultella planticola is found to have
similar pathogenetic features as Klebsiella spp. which are
associated with severe infections in fragile patients, as:
bacteraemias, pneumonias, and urinary tract infections
(Olson et al. 2013; Cho et al. 2016).
Common virulence factors between Klebsiella spp. and
RP has been investigated finding that both, Klebsiella
pneumoniae and RP, have type 1 fimbriae and mannose-
sensitive haemagglutination; furthermore Klebsiella spp.
have the ability to resist the bactericidal effects of human
serum, a feature that is shared by RP (Mertens et al. 2010).
This paper describes the case of a haemato-oncologic
patient, suffering from chemotherapy induced oral
mucositis, who developed a RP infection in the orophar-
ynx. To our knowledge no previous case, in terms of
pathogen and localisation, has been reported.
Case report
A 16-years-old boy was hospitalised with a diagnosis of
stage 3 Burkitt’s lymphoma, treated following the AIEOP
LNH97 therapeutic protocol (risk group 2), which includes
twice weekly Cotrimoxazole prophylaxis. According to the
Multinational Association of Supportive Care in Cancer
and International Society for Oral Oncology (MASCC/
ISOO) guidelines on dental management of paediatric
patients receiving chemotherapy, the boy underwent a
dental assessment before the chemotherapy. No caries or
periodontal lesions were detected and the oral hygiene
grade was good. During the second cycle A (an intense
5 days combination of Vincristine, Methotrexate, Ifos-
famide, Cytarabine and Etoposide) the patient developed a
chemotherapy-induced oral mucositis grade 3, according to
WHO scale (Sonis et al. 2004). Oral manifestations
included atrophic lesions of the cheeks, erosions of the
palate and of the lips, ulcers on both palatine pillars;
associated symptoms were pain and extreme difficulty in
chewing and swallowing food (Fig. 1). To exclude a con-
comitant bacterial infection, a swab of the lesions was
taken. After 2 days the sample grew RP. An antibiogram
was performed (ST-N204 Vitek-II card, based on the
EUCAST guideline), resulting in a completely sensitive
bacterium, with good susceptibility to all the tested
antibiotics, including Cotrimoxazole (MIC B 20 lg/mL).
In the meantime the ulcers had grown in size (almost 3 cm
after 5 days) and turned grey in colour, leading to increased
dysphagia and pain (severity 8/10). The patient also
experienced a febrile neutropaenia (0.05 9 109 WBC/L).
He had a C-reactive protein of 160 mg/L and a procalci-
tonin of 0.6 lg/L.
Treatment
Following assessment of the antibiogram, a combination
therapy with intravenous Amikacin and Ceftazidime was
commenced. The patient also received G-CSF and his fever
resolved within 72 h. The boy underwent a complete bio-
chemical assessment with repeated blood and urine cultures,
viral PCR and multiple swabs without any other positive
finding. Complete healing of the mucosal lesions and resolu-
tion of the symptoms were reached after 8 days of antibiotics
(Fig. 2).
Fig. 1 Sixteen-years-old male with chemotherapy-induced oral
mucositis grade 3, showing atrophic lesions of the cheeks, erosions
of the palate and of the lips, with ulcers on both palatine pillars
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Follow-up
The boy was discharged free of symptoms, with normal
blood values and continued his chemotherapy as scheduled
without delay. Now, 12 months after the infection, he is
alive and well, with no oral complains.
Discussion
The development of new chemotherapeutic and biological
agents has resulted in a substantial decrease in cancer
related death rates. Unfortunately, these treatment options
are often associated with profound immunosuppression,
mucosal damage and thus carry an increased risk of
infection. Neutropaenia—not only quantitative but also
qualitative—remains the most common adverse event of
anti-neoplastic chemotherapy (Nesher and Rolston 2014).
These defects include significant reduction in phagocytosis,
decreased bactericidal and fungicidal activity, decreased
production of superoxide anions, and defects in granulo-
cyte locomotion. Infectious events can negatively impact
survival directly and indirectly by causing dose reduction
or delays in anti-neoplastic therapy. Under strict hygiene
measures, most microbiologically documented infections
arise from the patient’s endogenous micro-flora, with only
a small proportion being acquired from exogenous sources
or as a result of environmental exposure. Patients with
severe oral mucositis are likely to have infections caused
by viridans group Streptococci (VGS) and Stomatococcus
mucilaginosus but coagulase-negative Staphylococci,
Klebsiella pneumoniae, Pseudomonas aeruginosa, and
Escherichia coli are also often encountered beside
microorganisms of the normal oral flora (Nesher and Rol-
ston 2014). Several recent epidemiologic surveys in adult
and paediatric patients from various parts of the globe have
documented the predominance of Gram-positive organisms
over Gram-negative bacilli as causes of microbiologically
documented infections in neutropaenic patients (Nesher
and Rolston 2014). Some of the reasons for this predomi-
nance include the almost universal use of central venous
catheters in such patients, the use of antimicrobial pro-
phylaxis directed primarily against enteric Gram-negative
bacilli, and last but not least the frequent use of
chemotherapy that produces significant oral mucositis
(Nesher and Rolston 2014).
Raoultella planticola is an emerging pathogen: in a
review conducted by Ershadi et al. (2014), a total of 17
cases of severe infection (dated from 1984 to 2014) were
reported, i.e. six patients with bacteraemia, four patients
with infections of the gastrointestinal tract, three patients
with skin and soft tissues infections, three patients with
pneumoniae and one patient with cystitis. Nine infections
were confirmed to be nosocomial, six of which involved
immunocompromised patients. Three patients who devel-
oped bacteraemia died, due to multi-drug resistance strains.
Various authors suggest at least four possible scenarios that
could make a patient develop an infection with this
pathogen: (a) inoculation of a significant load of bacteria in
a immunologically and/or anatomically injured site, due to
trauma in a contaminated environment (community
acquired; O’Connell et al. 2010; Kim et al. 2012); (b) in-
troduction of the pathogen through invasive hospital pro-
cedures (nosocomial infection; Freney et al. 1984; Kim
et al. 2012; (c) activation of dormant colonies in
immunocompromised patients (Alves et al. 2007; Yokota
et al. 2012) (d) enteric fever and bacteraemia in immuno-
competent individuals (fish poisoning; Puerta-Fernandez
et al. 2013). Extended post-hoc anamnesis did not reveal
any recent fish intake (though he had close contact with
farm animals) or particular trauma prior to chemotherapy,
which makes reactivation of dormant colonies the most
probable mechanism in this patient.
Conclusions
One of the frequently overlooked complications of
chemotherapy is oral mucositis. This condition can range
from mild to severe and represents a common cause of
chemotherapy dose reduction and treatment delays as well
as infections. Chemotherapy-related oral infections, which
account for 25–50% of the total infections, contribute
significantly to the morbidity and mortality in these
patients. This case report highlights the need to now add
Raoultella planticola to the list of bacteria encountered in
the course of oral mucositis in patients undergoing
chemotherapy.
Fig. 2 Complete healing of the mucosal lesions and resolution of the
symptoms after 8 days
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